FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians, Eight Years Running!
May 02 2023 - 1:59PM
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce
that FeraMAX® is the #1 recommended iron supplement brand in
Canada, based on a national survey of Canadian pharmacists and
physicians(1). This is the eighth consecutive year that FeraMAX®
has been awarded this vote of confidence.
The annual Survey on OTC Counselling and
Recommendations is an important pharmaceutical industry indicator
which tracks pharmacist and physician counselling patterns for
over-the-counter (OTC) products in Canada. The survey was fielded
between October 2022 and January 2023 by EnsembleIQ Research and
Innovation: Pharmacy Practice + Business, The Medical Post,
Profession Santé, CanadianHealthcareNetwork.ca, and
ProfessionSanté.ca. This is the only national survey to research
the role of Canadian pharmacists and physicians as counsellors and
advisors in non-prescription products.
“We thank Canadian physicians and pharmacists
for their growing trust and confidence in the FeraMAX® brand for
eight years in a row,” commented René Goehrum, President and CEO of
BioSyent. “Healthcare professionals are essential in supporting the
iron health of Canadians and BioSyent continues to provide
innovative solutions, supportive continuing education, and
patient-focused resources to our healthcare partners.”
About
FeraMAX®
The FeraMAX® Pd brand has a unique, patented
Polydextrose-Iron Complex (PDIC) formulation and all versions of
FeraMAX® are dosed once daily, supporting iron health with
treatment, maintenance and preventative supplements.
FeraMAX®
Pd Therapeutic 150 is an oral iron supplement
indicated for the treatment of iron deficiency anemia.
FeraMAX®
Pd Powder 15 makes iron therapy convenient for
children. On March 7th 2023, BioSyent announced an important
addition to the FeraMAX® family of iron supplements with
FeraMAX®
Pd Maintenance 45 designed to prevent iron
deficiency, maintain healthy iron levels, and to address a gap in
iron health therapy. The FeraMAX® family represents innovative
solutions to support iron health across various life stages.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community,
specialty, and international business units.
As of the date of this press release, the
Company has 12,091,919 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
- Reference for
ranking:Pharmacy Practice + Business, The Medical Post and
Profession Santé 2023 Survey on OTC Counselling and
Recommendations.
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2024 to May 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2023 to May 2024